Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consider Lilly: why the gloomy guidance?

This article was originally published in Scrip

Executive Summary

Greater pessimism over generic erosion of Zyprexa sales and higher spending on SG&A are the principal reasons that Lilly's financial guidance for 2012, issued on 5 January, falls short of analyst expectations. This was the explanation given by the firm's CFO, Derica Rice, who declared that the company had already done most of its cost-cutting, having begun early (in 2004, since when net headcount has been cut by 16%) to prepare for its patent cliff moment, which it terms the 'YZ period'. This period covers the patent expiry of its top-selling antipsychotic drug Zyprexa (olanzapine) in late 2011 through to the expiry of its antidepressant drug Cymbalta (duloxetine) in the US at the end of 2013.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts